论文部分内容阅读
伐昔洛韦(valaciclovir)是抗病毒药物阿昔洛韦的前体药物,生物利用度优于阿昔洛韦。美国药典通用名盐酸伐昔洛韦。我国已于1996年批准上市,现将其药理作用及临床应用简介如下: 1 药理作用 1.1 药效学 对疱疹性病毒I(HSV-Ⅰ)和疱疹性病毒Ⅱ(HSV-Ⅱ)的抑制作用强,对水痘疱疹病毒、非洲淋巴细胞瘤病毒以及巨细胞病毒抑制作用弱。本品毒性小,治疗指数高,药效优于阿昔洛韦(ACV)。对vero细胞毒性比ACV低46.9％。对HSV—1、HSV—Ⅱ的治疗指数ACV高42.9％和30.1％。本品体内抗病毒活性亦优于ACV。l 141例临床结果表明,本品1000mg,tid,连服7和14d与ACV 800mg每日5次,连服7d比较,对带状疱疹疼痛的缓解明显优于ACV。
Valaciclovir is a prodrug of the antiviral acyclovir, which is more bioavailable than acyclovir. The United States Pharmacopoeia common name valacyclovir hydrochloride. China has approved the listing in 1996, and now its pharmacological effects and clinical applications are as follows: 1 Pharmacological effects 1.1 pharmacodynamics on the herpes virus I (HSV-Ⅰ) and herpes virus Ⅱ (HSV-Ⅱ) strong inhibitory effect , Has a weak inhibitory effect on Chickenpox herpes virus, African lymphocytoma virus and cytomegalovirus. This product is less toxic, high therapeutic index, efficacy is better than acyclovir (ACV). Cytotoxicity to vero is 46.9% lower than ACV. HSV-1, HSV-Ⅱ treatment index ACV high 42.9% and 30.1%. This product is also superior to the antiviral activity of ACV. l 141 cases of clinical results show that the product 1000mg, tid, and even served 7 and 14d and ACV 800mg 5 times a day, even for 7d, the relief of herpes zoster pain was significantly better than ACV.